Autologous hALK.CAR T cells therapy(Boston Children's Hospital)

N/A

Report date: 2025/02/07 20:00:46

Base Information

Drug NameAutologous hALK.CAR T cells therapy(Boston Children's Hospital)
Drug Alias NameAutologous chimeric antigen receptor T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor therapy(Boston Children's Hospital)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnaplastic lymphoma kinase modulatorsT lymphocyte replacements
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoston Children'S HospitalDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBoston Children'S Hospital
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A